Skip to main content
SpringerLink
Log in

Arterial Hypertension: What Is the Optimal Goal of Treatment?

  • Chapter
  • First Online:
Management of Hypertension

  • 1065 Accesses

Abstract

Landmark clinical trials have proved that the use of antihypertensive drugs reduces the risk of cardiovascular events occurrence, including incident stroke, myocardial infarction and heart failure. In contrast to the past, when hypertension was considered essential for the perfusion of vital organs, the benefit of lowering blood pressure levels is considered now invaluable, especially among high risk populations. However, the optimal blood pressure goal is still debated. This chapter focuses primarily on milestone studies and on updated evidence-based clinical HTN guidelines. More specifically, it reviews the MRC,the HDFP,the HOT, the SPRINT, the ACCORD and the HOPE-3 studies, and discusses the suggested optimal BP goals derived from these trials. It also focuses on interesting meta-analyses stratifying the different trials according to the BP levels achieved by active treatment.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 109.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 139.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Roguin A. Scipione Riva-Rocci and the men behind the mercury sphygmomanometer. Int J Clin Pract. 2006;60:73–9.

    Article  CAS  Google Scholar 

  2. Korner PI. Essential hypertension and its causes: neural and non-neural mechanisms. Oxford/New York: Oxford University Press. ISBN 978-0-19-535740-0.

  3. Rossi GP. The challenges of arterial hypertension. Front Cardiovasc Med. 2015;2:2.

    Article  Google Scholar 

  4. Chrysant SG. Current status of aggressive blood pressure control. World J Cardiol. 2011;3:65–71.

    Article  Google Scholar 

  5. White PD. Heart disease. 3rd ed. New York: MacMillan; 1944. Zanchetti A. Hypertension: past, present, and future. Rev Fed Arg Cardiol. 2015;44.

    Google Scholar 

  6. Bishop T, Figueredo VM. Hypertensive therapy: attacking the renin-angiotensin system. West J Med. 2001;2:119–24.

    Article  Google Scholar 

  7. Bumgarner J. The health of the presidents: the 41 United States presidents through 1993 from a physician’s point of view. Jefferson: McFarland & Company, Inc.; 1994.

    Google Scholar 

  8. Deppisch LM. The White House physician: a history from Washington to George W. Bush. Jefferson: McFarland & Company; 2007.

    Google Scholar 

  9. Evans H. The hidden campaign: FDR’s health and the 1944 election. Armonk: M.E. Sharpe; 2002.

    Google Scholar 

  10. Fye WB. Caring for the heart: Mayo Clinic and the rise of specialization. Oxford: Oxford University Press; 2015.

    Google Scholar 

  11. Freis ED. Reminiscences of the Veterans Administration trial of the treatment of hypertension. Hypertension. 1990;16(4):472–5.

    Article  CAS  Google Scholar 

  12. Kannel WB, Wolf PA, Veter J, McNamara PM. Epidemiologic assessment of the role of blood pressure in stroke. JAMA. 1970;214:301–10.

    Article  CAS  Google Scholar 

  13. Kannel WB, Schwartz MJ, McNamara PM. Blood pressure and risk of coronary heart disease: the Framingham study. Dis Chest. 1969;56:43–52.

    Article  CAS  Google Scholar 

  14. Andreadis EA. Hypertension: a growing threat. In: Andreadis EA, editor. Hypertension and cardiovascular disease. Cham: Springer Nature; 2016. p. 1–17.

    Chapter  Google Scholar 

  15. WHO. Global status report on noncommunicable diseases 2014. World Health Organization, Geneva; 2015.

    Google Scholar 

  16. Chockalingam A, Campbell NR, Fodor JG. Worldwide epidemic of hypertension. Can J Cardiol. 2006;22:553–5.

    Article  Google Scholar 

  17. Kearney PM, Whelton M, Reynolds K, Muntner P, Whelton PK, He J. Global burden of hypertension: analysis of worldwide data. Lancet. 2005;365:217–23.

    Article  Google Scholar 

  18. O’Donnell MJ, Xavier D, Lio L, Zhang H, Chin SL, Rao-Melacin P, et al. Risk factors for ischemic and intracerebral hemorrhage stroke in 22 countries (the INTERSTROKE study): a case-control study. Lancet. 2010;376:112–23.

    Article  Google Scholar 

  19. Yusuf S, Hawken S, Ounpuu S, Dans T, Avezum A, Lanas F, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study); case-control study. Lancet. 2004;364:937–52.

    Article  Google Scholar 

  20. Botdorf J, Chaudhary K, Whaley-Connell A. Hypertension in cardiovascular and kidney disease. Cardiorenal Med. 2011;1:183–92.

    Article  Google Scholar 

  21. Murabito JM, D’Agostino RB, Silbershtz H, Wilson WF. Intermittent claudication: a risk profile from the Framingham Heart Study. Circulation. 1997;96:44–9.

    Article  CAS  Google Scholar 

  22. World Health Organization. A global brief on hypertension: silent killer, global public health crisis 2013. http://www.who.int/cardiovascular_diseases/publications/global_brief_hypertension/en/. Accessed 31 Aug 2014.

  23. Forouzanfar MH, Liu P, Roth GA, et al. Global burden of hypertension and systolic blood pressure of at least 110 to 115 mm Hg, 1990–2015. JAMA. 2017;317:165–82.

    Article  Google Scholar 

  24. Bakris GL, Frohlich ED. An overview of four decades of experience. JACC. 1989;7:1595–608.

    Article  Google Scholar 

  25. Rutan GH, McDonald RH, Kuller LH. A historical perspective of elevated systolic vs diastolic blood pressure from an epidemiological and clinical trial viewpoint. J Clin Epidemiol. 1989;7:663–73.

    Article  Google Scholar 

  26. MRC Trial of treatment of mild Hypertension: principal results. Medical Research Council Working Party. Br Med J. 1985;291:97–104.

    Google Scholar 

  27. Zhang X, Fan F, Huo Y, Xu X. Identifying the optimal blood pressure target for ideal health. J Transl Intern Med. 2016;4:1–6.

    Article  CAS  Google Scholar 

  28. Hypertension Detection and Follow-Up Program Cooperative Group. Five-year findings of the hypertension detection and follow-up program. I. Reduction in mortality of persons with high blood pressure, including mild hypertension. JAMA. 1979;242:2562–71.

    Article  Google Scholar 

  29. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity and hypertension: results in patients with diastolic pressures averaging 115 through 129 millimeters of mercury. JAMA. 1967;202:1028–34.

    Article  Google Scholar 

  30. Veterans Administration Cooperative Study Group on Antihypertensive Agents. Effects of treatment on morbidity and hypertension. II. Results in patients with diastolic blood pressure averaging 90 through 114 millimeters of mercury. JAMA. 1970;213:1143–52.

    Article  Google Scholar 

  31. Hansson L, Zanchetti A, Carruthers SG, Dahlof B, Elmfeldt D, Julius S, et al. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet. 1998;351:1755–62.

    Article  CAS  Google Scholar 

  32. Mancia G, Fagard R, Narkiewicz K, et al. 2013 ESH/ESC guidelines for the management of arterial hypertension. J Hypertens. 2013;31:1281–357.

    Article  CAS  Google Scholar 

  33. James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eight Joint National Committee (JNC 8). JAMA. 2014;311:507–20.

    Article  CAS  Google Scholar 

  34. Wright JT Jr, Williamson JD, Whelton PK, Snyder JK, Sink KM, Rocco MV, et al. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373:2103–16.

    Google Scholar 

  35. Kjeldsen SE, Mancia G. Unobserved automated office blood pressure measurement in the systolic blood pressure intervention trial (SPRINT): systolic blood pressure treatment target remains below 140 mmHg. Eur Heart J Cardiovasc Pharmacother. 2016;2:79–80.

    Article  Google Scholar 

  36. Parati G, Ochoa JE, Bilo G, Zanchetti A. SPRINT blood pressure: sprinting back to Smirk's basal blood pressure? Hypertension. 2017;69:15–9.

    Article  CAS  Google Scholar 

  37. Ettehad D, Emdin CA, Kiran A, et al. Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet. 2016;387:957–67.

    Article  Google Scholar 

  38. Bangalore S, Toklu B, Gianos E, Schwartzbard A, Weintraub H, Ogedegbe G, et al. Optimal systolic blood pressure target after SPRINT: insights from a network meta-analysis of randomized trials. Am J Med. 2017;130(6):707–719 e8.

    Article  Google Scholar 

  39. Zanchetti A, Liu L, Mancia G, Parati G, Grassia G, MarcoStramba-Badialea M, et al. Continuation of the ESH-CHL-SHOT trial after publication of the SPRINT: rationale for further study on blood pressure targets of antihypertensive treatment after stroke. J Hypertens. 2016;34:393–5.

    Article  CAS  Google Scholar 

  40. Williamson JD, Supiano MA, Applegate WB, Berlowitz DR, Campbell RC, Chertow GM, et al. Intensive vs standard blood pressure control and cardiovascular disease outcomes in adults aged ≥75 years. JAMA. 2016;315:2673–82.

    Article  CAS  Google Scholar 

  41. Cushman WC, Evans GW, Byington RP, Goff DC, Grimm RH, Cutler JA. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362:1575–85.

    Article  Google Scholar 

  42. Yusuf S, Lonn E, Pais P, Bosch J, Lopez-Jaramillo P, Zhu J, et al. Blood-pressure and cholesterol lowering in persons without cardiovascular disease. N Engl J Med. 2016;374:2032–43.

    Article  CAS  Google Scholar 

  43. Chobanian AV. Hypertension in 2017-what is the right target? JAMA. 2017;317:579–80.

    Article  Google Scholar 

  44. Thomopoulos C, Parati G, Zanchetti A. Effects of blood pressure lowering on outcome incidence in hypertension. 7. Effects of more versus less intensive blood pressure lowering and different achieved blood pressure levels-updated overview and meta-analyses of randomized trials. J Hypertens. 2016;34:613–22.

    Article  CAS  Google Scholar 

  45. Whelton PK, et al. 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA guideline for the prevention, detection, evaluation, and Management of High Blood Pressure in adults. JACC. 2018;71:e127–248. https://doi.org/10.1016/j.jacc.2017.11.006.

    Article  PubMed  Google Scholar 

  46. Handler J. The importance of accurate blood pressure measurement. Perm J. 2009;13:51–4.

    Article  Google Scholar 

  47. Bakris G, Sorrentino M. Redefining hypertension — assessing the new blood-pressure guidelines. NEJM. 378:497–9. https://doi.org/10.1056/NEJMp1716193.

    Article  Google Scholar 

  48. Moise N, Huang C, Rodgers A, Kohli-Lynch CN, Tzong KY, Coxson PG, et al. Comparative cost-effectiveness of conservative or intensive blood pressure treatment guidelines in adults aged 35–74 years the cardiovascular disease policy model. Hypertension. 2016;68:88–96.

    Article  CAS  Google Scholar 

  49. Freis ED. Hypertension treatment: contributions and comments on challenges. J Clin Hypertens. 2004;1:45–6.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Hypertension and Cardiovascular Disease Prevention Center, Evangelismos General Hospital, Athens, Greece

    Emmanuel A. Andreadis

  2. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Emmanuel A. Andreadis & Charalampia V. Geladari

  3. Department of Medicine, Division of Cardiology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, MA, USA

    Charalampia V. Geladari

Authors
  1. Emmanuel A. Andreadis
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Charalampia V. Geladari
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Georgetown University and VA Medical Center, Washington, DC, USA

    Vasilios Papademetriou

  2. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Emmanuel A. Andreadis

  3. Fourth Internal Medicine Department, Evangelismos State General Hospital, Athens, Greece

    Charalampia Geladari

Rights and permissions

Reprints and permissions

Copyright information

© 2019 Springer International Publishing AG, part of Springer Nature

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Andreadis, E.A., Geladari, C.V. (2019). Arterial Hypertension: What Is the Optimal Goal of Treatment?. In: Papademetriou, V., Andreadis, E., Geladari, C. (eds) Management of Hypertension. Springer, Cham. https://doi.org/10.1007/978-3-319-92946-0_13

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-92946-0_13

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-92945-3

  • Online ISBN: 978-3-319-92946-0

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation